Please assess the completion status of the following clinical trial:

Trial Title: Topical Sm29 in Combination With Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- Clinical diagnosis of cutaneous leishmaniasis (typical ulcerated lesion); 1 to 2 ulcers; ulcer size ranging from 10-40mm; disease duration between 20-90 days.~Exclusion Criteria:~* Diabetes; Cardiovascular or kidney disease; HIV seropositivity; use of immunosupressive drugs; pregnancy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Topical Sm29 and Sbv (Type: EXPERIMENTAL): Use of topical Sm29 twice a day during 20 days and systemic Sbv during 20 days
- Topical Placebo and Sbv (Type: PLACEBO_COMPARATOR): Use of topical placebo twice a day during 20 days and systemic Sbv during 20 days

Based on this trial design, predict the completion outcome and termination type (if applicable).